RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial

MT Newswires Live11-20 22:40

RenovoRx (RNXT) said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.

The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.

Shares of RenovoRx were up more than 4% in early morning trade.

Price: 1.16, Change: +0.05, Percent Change: +4.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484424117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484424117","market":"us","top_or_hot":-1,"title":"RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> RenovoRx (RNXT) said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.</p><p>The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.</p><p>Shares of RenovoRx were up more than 4% in early morning trade.</p><p>Price: 1.16, Change: +0.05, Percent Change: +4.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 22:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RenovoRx (RNXT) said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484424117","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484424117","pubTimestamp":1732113613,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"RenovoRx  said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.Shares of RenovoRx were up more than 4% in early morning trade.Price: 1.16, Change: +0.05, Percent Change: +4.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","III":"信息服务","BK4134":"信息科技咨询与其它服务","RNXT":"RenovoRx Inc","BK4139":"生物科技"},"translate_title":"RenovoRx表示诺斯威尔健康癌症研究所开始招募患者进行III期胰腺癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"RNXT":1},"content_text":"RenovoRx (RNXT) said Wednesday that New York-based Northwell Health Cancer Institute started enrolling patients with advanced pancreatic cancer in an ongoing phase III trial that will evaluate the Trans-Arterial Micro-Perfusion therapy platform.The study will use RenovoRx's TAMP therapy platform to evaluate its first drug-device combination product candidate, which is an intra-arterial infusion of gemcitabine via the RenovoCath delivery system. The study will compare treatment with TAMP versus the current standard-of-care chemotherapy, according to the company.Shares of RenovoRx were up more than 4% in early morning trade.Price: 1.16, Change: +0.05, Percent Change: +4.32","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484424117"}